Gustav Christensen

Gustav Christensen is chairman of Morphic Therapeutic, a public biotech company. He was the president and chief executive officer of Dyax from 2009 until it was acquired by Shire for $6.4 billion in 2016. He joined Dyax in early 2007 as the executive vice president and chief business officer. Gustav began his career at Baxter International, with his last position being the vice president of operations of the Fenwal Laboratories division. He left in 1983 to become the vice president of business development at the Genetics Institute. Gustav received his Master of Science in economics from the University of Aarhus, Denmark, and his MBA from Harvard Business School.